Dr Tanjina Kader – Harvard Medical School

12/02/2024 3:00 pm - 12/02/2024 4:00 pm
Davis Auditorium

WEHI Special ACRF Cancer Biology & Stem Cells Seminar hosted by Dr Ksenija Nesic

Dr Tanjina Kader
Post-doctoral Fellow in the Harvard Program in Therapeutic Science, Harvard Medical School

Multimodal spatial profiling reveals the emergence of an immune suppressive microenvironment at the initial stages of high-grade serous cancer development 


Davis Auditorium

Join via TEAMS

Including Q&A session


Despite the clear genetic evidence linking serous tubal intraepithelial carcinoma (STIC) and high-grade serous ovarian carcinoma (HGSOC), the specific conditions and events that promote the progression of STIC lesions into invasive disease remain poorly understood. A comprehensive understanding of the molecular and cellular interactions occurring in the earliest stages of HGSOC development is therefore needed. As a critical initial step, we have assembled a cohort of incidental p53 signatures, STIC lesions, and STIC with concurrent HGSOC, as a part of a collaboration with A/Prof Ronny Drapkin (UPenn). We are currently working on integrating the multi-modal analysis with the cBioportal team (MSKC, DFCI) to make the data publicly available.  


Dr Tanjina Kader is a Post-doctoral Fellow in the Harvard Program in Therapeutic Science under the supervision of Otto Krayer Prof Peter Sorger, and A/Prof Sandro Santagata at Harvard Medical School (HMS; Boston, USA). She utilizes multi-modal spatial profiling to investigate the progression of High-Grade Serous Ovarian Carcinoma as a part of the Pre-cancer Atlas program. Dr Kader obtained her PhD in Cancer Genetics at the Sir Peter MacCallum Cancer Centre (PMCC), Department of Oncology, University of Melbourne (2019) under the supervision of A/Prof Kylie Gorringe and Prof Ian Campbell. She stayed on as a Post-doctoral researcher in the Cancer Evolution and Metastasis Program at PMCC from 2020-2022 under the supervision of A/Prof Kylie Gorringe. There, she investigated the progression of breast cancer from breast pre-malignant and pre-invasive disease using in situ assays and next-generation sequencing. She was awarded a post-doctoral Fellowship from Cancer Council Victoria in 2020 and was a co-PI on a Cancer Australia/NBCF grant (2021-2024) to validate an immune combined biomarker to deescalate the treatment of breast precancers with A/Prof Kylie Gorringe. Dr Kader has been internationally recognized for her work on DCIS recurrences at the Annual Meetings of AACR in 2022, leading to media releases and press conferences related to her findings.  . 


All welcome!

Support us

Together we can create a brighter future

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Sign up to our quarterly newsletter Illuminate

Find out about recent discoveries, community supporters and more.

Illuminate Summer 2023
View the current issue